Company intelligence / Profile preview
Inibio
Hwaseong-si, Gyeonggi-do, South Koreainibio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Inibio is a South Korean biotechnology company specializing in the development and manufacture of botulinum toxin products for medical and aesthetic applications. The company's lead candidate, INI101, is a high-purity botulinum toxin type A designed to treat glabellar lines and other neuromuscular conditions. Inibio utilizes advanced fermentation and purification technologies to ensure product safety and competitive efficacy. The company operates a dedicated GMP-compliant manufacturing facility in Hwaseong to support its global commercialization strategy. Inibio is actively pursuing international market entries through clinical trials and strategic distribution partnerships.
- Therapeutic areas
- NeurologyDermatology
- Modalities
- BiologicProtein
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Inibio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inibio.